Physician profile
Andrew Johnson Mcdavid
NPI 1477514479
$10,918.19
in general payments reported to CMS, 2019-2025
24 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $2,203 · 2021: $2,614 · 2022: $1,959 · 2023: $606 · 2024: $1,238 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,336.15 | 2019-2025 | Proclaim, Eterna, Octrode |
| Abbvie INC. | $850.58 | 2021-2025 | |
| Boston Scientific Corporation | $426.63 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, General - Therapies |
| Vertos Medical, INC. | $236.68 | 2021-2022 | |
| Curonix LLC | $196.62 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $137.27 | 2022-2024 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $93.55 | 2025 | |
| Stimwave Technologies Incorporated | $70.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $59.50 | 2024 | Keveyis |
| Vertiflex, INC. | $59.00 | 2019 | |
| Foundation Fusion Solutions, LLC | $57.00 | 2024 | |
| Mml US, INC. | $56.81 | 2023-2025 | Reactiv8 |
| Relievant Medsystems, INC. | $43.75 | 2022 | |
| Medtronic, INC. | $43.04 | 2024-2025 | Synchromedii, Inceptiv |
| Depuy Synthes Sales INC. | $33.79 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $31.53 | 2023 | Iovera, Zilretta |
| Medtronic USA, INC. | $31.37 | 2019 | |
| Pacira Therapeutics, INC. | $28.63 | 2021 | |
| Pfizer INC. | $24.18 | 2020-2021 | |
| Ibsa Pharma INC. | $23.50 | 2025 | Tirosint, Flector, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.73 | 2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $20.27 | 2022 | |
| Valinor Pharma, LLC | $20.21 | 2025 | Movantik |
| Biodelivery Sciences International, INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcdavid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.